Muscle Disorders

AAD: Significant Benefits Seen for Brepocitinib 30 mg in Dermatomyositis

Physician’s Briefing

AAD: Significant Benefits Seen for Brepocitinib 30 mg in Dermatomyositis

01 Apr 2026

2 min read

FDA Approves Itvisma for Spinal Muscular Atrophy

Physician’s Briefing

FDA Approves Itvisma for Spinal Muscular Atrophy

08 Dec 2025

1 min read

FDA Grants Accelerated Approval for First Treatment for Barth Syndrome

Physician’s Briefing

FDA Grants Accelerated Approval for First Treatment for Barth Syndrome

25 Sep 2025

1 min read

Read More

Clinical Briefing Report

clinicalbriefingreport.com